Due to the nature of C. diff infections, particularly the high recurrence rate following standard treatments, participating in a clinical trial may be an option for sufferers who don’t respond to antibiotics. Some clinical trials focus on developing vaccines and other preventatives. While Peggy Lillis Foundation does not endorse specific treatments, we make C. diff patients aware of clinical trials, which may benefit them.

A New Player in the C. diff Treatment Space

Vedanta is a late-stage clinical biotechnology company developing first-in-class oral therapies for the treatment of serious gastrointestinal diseases. VE303 is an investigational treatment for patients with recurrent C. difficile infections (CDI). VE303 is a preparation of eight different types of bacteria grown in clean conditions, dried, powdered and put into capsules to be administered orally.

RESTORATiVE303 is their Phase III clinical research study that is exploring the investigational drug to restore the microbiome in people with recurrent C. diff. There are study sites across the US and Canada. Find a study site and read more about the study here.

Vedanta has teamed up with Science37 to provide a site-less, decentralized approach. This means the study can be done remotely and the product comes to you, in your home. This allows applicants who are not near a study site or unable to travel to participate and receive treatment. You can sign up for the decentralized study here.